Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19754775 | 0.82 | LMNA (0.33) | GSK3AGSK3B | |
| SCHEMBL18925632 | 0.82 | MAPK1 (0.35) | GSK3AGSK3B | |
| SCHEMBL27215058 | 0.81 | DYRK1B (0.41) | GSK3AGSK3B | |
| SCHEMBL21893429 | 0.81 | JAK2 (0.32) | GSK3AGSK3B | |
| SCHEMBL1496185 | 0.81 | GSK3B (0.36) | GSK3B | |
| SCHEMBL18352531 | 0.78 | METAP2 (0.31) | — | |
| SCHEMBL19754776 | 0.78 | PRMT5 (0.34) | — | |
| SCHEMBL19209822 | 0.77 | — | — | |
| SCHEMBL18366470 | 0.76 | SMN1; SMN2 (0.36) | GSK3B | |
| SCHEMBL18366477 | 0.76 | HCAR2 (0.38) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K20, MAP3K19, MAP3K1 | GSK3A 342/4885GSK3B 358/4885 |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | GSK3A 751/4885GSK3B 868/4885 |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K20, MAP3K19, MAP3K1 | GSK3A 342/4885GSK3B 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.